About WebBasedCME.com
Applying the latest technological advances in education and message broadcasting, WebBasedCME.com will distribute
ease-of-access pertinent information directly to the professionals that desire to keep up-to-date with medical
breakthroughs.
more...
More Online CME Resources
The Caring For Diabetes Educational Forum
Case Based CME - The Amazing Race to Tight Glycemic Control
American Academy of Family Physicians
Medscape - CME Center
Activities
Current CME Activities
DIABETES :: Applied Practical Learning
No Sugar Coating Required: Real-Life Application of Incretin-Based Therapies in Type 2 Diabetes
Incretin-based therapies, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, provide effective glycemic control in type 2 diabetes (T2D), paired with beneficial nonglycemic effects on weight, lipids, and blood pressure.
This unique program will highlight the comparative effectiveness and safety of these agents, appropriate patient selection, timely treatment initiation, and common barriers to glycemic control through the use of a simulated patient.
This activity is intended for osteopathic physicians who treat patients with T2D.
Incretin-based therapies, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, provide effective glycemic control in type 2 diabetes (T2D), paired with beneficial nonglycemic effects on weight, lipids, and blood pressure.
This unique program will highlight the comparative effectiveness and safety of these agents, appropriate patient selection, timely treatment initiation, and common barriers to glycemic control through the use of a simulated patient.
This activity is intended for osteopathic physicians who treat patients with T2D.
DIABETES :: Online Activity
Hot Seat Discussion on GLP-1 Receptor Agonists ...Your Questions Answered
Recent clinical trials have demonstrated the therapeutic efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) at different stages of diabetes progression, and exploratory studies suggest the potential for therapeutic uses other than glycemic control in patients with type 2 diabetes mellitus (T2DM). This continuing medical education (CME/CE) symposium will focus on hot topics arising from the most current information relevant to GLP-1 RAs.
This activity includes an introductory segment followed by 8 "hot topic" discussions, each consisting of comparative answer polling questions; a short written excerpt of relevant, corresponding clinical data; and audio clips of the faculty roundtable discussion derived from questions received during the live activity.
Recent clinical trials have demonstrated the therapeutic efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) at different stages of diabetes progression, and exploratory studies suggest the potential for therapeutic uses other than glycemic control in patients with type 2 diabetes mellitus (T2DM). This continuing medical education (CME/CE) symposium will focus on hot topics arising from the most current information relevant to GLP-1 RAs.
This activity includes an introductory segment followed by 8 "hot topic" discussions, each consisting of comparative answer polling questions; a short written excerpt of relevant, corresponding clinical data; and audio clips of the faculty roundtable discussion derived from questions received during the live activity.
DIABETES :: Applied Practical Learning
Tailoring Treatment for Type 2 Diabetes: Uncovering the HOW and NOW of GLP-1 Receptor Agonist Therapy
This activity, and the live symposium on which it is based, were supported by an education grant from Novo Nordisk, Inc. The live symposium, “Tailoring Treatment for Type 2 Diabetes: Uncovering the HOW and NOW of GLP-1 Receptor Agonist Therapy,” presented Thursday, March 17, 2011, at the American College of Osteopathic Family Physicians’ (ACOFP) 48th Annual Convention & Exhibition in San Antonio, Texas, was sponsored by the ACOFP and developed by the Institute for Medical and Nursing Education.
This activity, and the live symposium on which it is based, were supported by an education grant from Novo Nordisk, Inc. The live symposium, “Tailoring Treatment for Type 2 Diabetes: Uncovering the HOW and NOW of GLP-1 Receptor Agonist Therapy,” presented Thursday, March 17, 2011, at the American College of Osteopathic Family Physicians’ (ACOFP) 48th Annual Convention & Exhibition in San Antonio, Texas, was sponsored by the ACOFP and developed by the Institute for Medical and Nursing Education.
Past CME Activities
DIABETES :: Online Case Study
Identifying the Pathway to Successful Patient Care: Practical Implementation of Incretin-Based Therapies in Type 2 Diabetes
This activity is intended for family physicians and other HCPs who treat patients with T2D.
This activity is intended for family physicians and other HCPs who treat patients with T2D.
DIABETES :: Webcast Series
Prospects for GLP-1 Receptor Agonists: When, Who, and How to Treat
This activity is intended for physicians, nurses, nurse practitioners, physician assistants, certified diabetes educators, and other HCPs who care for patients with T2DM and manage the complications related to this disease.
This activity is intended for physicians, nurses, nurse practitioners, physician assistants, certified diabetes educators, and other HCPs who care for patients with T2DM and manage the complications related to this disease.
DIABETES :: Online Case Study
Optimizing Insulin Therapy: A Case-based Activity
This activity is intended for physicians, diabetes educators, nurses and other healthcare professionals who treat patients with diabetes.
This activity is intended for physicians, diabetes educators, nurses and other healthcare professionals who treat patients with diabetes.
DIABETES :: Monograph
Peak Issues 4: Clinical Use Of Incretin-Based Therapies To Treat Type 2 Diabetes
This program is intended for endocrinologists, diabetologists, and other healthcare professionals (HCPs) who frequently treat patients with 2 diabetes.
This program is intended for endocrinologists, diabetologists, and other healthcare professionals (HCPs) who frequently treat patients with 2 diabetes.
DIABETES :: Monograph
Peak Issues 3: Clinical Use Of Incretin-Based Therapies To Treat Type 2 Diabetes
This program is intended for endocrinologists, diabetologists, and other healthcare professionals (HCPs) who frequently treat patients with type 2 diabetes. This publication series will explore the science of PPG and its contribution to glycemic control, and highlight recent and emerging therapies that address this important target.
This program is intended for endocrinologists, diabetologists, and other healthcare professionals (HCPs) who frequently treat patients with type 2 diabetes. This publication series will explore the science of PPG and its contribution to glycemic control, and highlight recent and emerging therapies that address this important target.
ONCOLOGY :: Applied Practical Learning
Women's Oncology Masters Series: The Evolving Role of Targeted Therapy in Breast and Ovarian Cancers
This activity is intended for gynecologic oncologists, medical oncologists, surgical oncologists and other oncology HCPs who want to further the care of their patients with advanced breast cancer and ovarian cancer.
This activity is intended for gynecologic oncologists, medical oncologists, surgical oncologists and other oncology HCPs who want to further the care of their patients with advanced breast cancer and ovarian cancer.
DIABETES :: Webcast Series
Evolving Landscape of Incretin-Based Therapies Webcast
Type 2 diabetes is a progressive disease that often requires treatment intensification using several therapeutic agents. Incretin-based therapies address numerous pathophysiologic defects in type 2 diabetes with limited side effects.This content will discuss incretin-based therapies in depth, from pathophysiologic effects to clinical use, and will incorporate interactive questions whereby you can evaluate your answers against those of your colleagues, along with a concluding faculty panel discussion.
Type 2 diabetes is a progressive disease that often requires treatment intensification using several therapeutic agents. Incretin-based therapies address numerous pathophysiologic defects in type 2 diabetes with limited side effects.This content will discuss incretin-based therapies in depth, from pathophysiologic effects to clinical use, and will incorporate interactive questions whereby you can evaluate your answers against those of your colleagues, along with a concluding faculty panel discussion.
DIABETES :: Online Case Study
Cases in Practice: Incretin-Based Therapies for Common Patient Encounters
This activity is composed of 3 interactive case studies which explore options for the clinical use of incretin-based therapies in diverse clinical scenarios. Because each case study examines different aspects of diabetes care, completion of all 3 is expected to provide a broader perspective regarding the use of the 2 available classes of incretin-based therapies.
This activity is composed of 3 interactive case studies which explore options for the clinical use of incretin-based therapies in diverse clinical scenarios. Because each case study examines different aspects of diabetes care, completion of all 3 is expected to provide a broader perspective regarding the use of the 2 available classes of incretin-based therapies.
DIABETES :: Monograph
Peak Issues 2: Clinical Use Of Incretin-Based Therapies To Treat Type 2 Diabetes
This program is intended for endocrinologists, diabetologists, and other healthcare professionals (HCPs) who frequently treat patients with type 2 diabetes. This publication series will explore the science of PPG and its contribution to glycemic control, and highlight recent and emerging therapies that address this important target.
This program is intended for endocrinologists, diabetologists, and other healthcare professionals (HCPs) who frequently treat patients with type 2 diabetes. This publication series will explore the science of PPG and its contribution to glycemic control, and highlight recent and emerging therapies that address this important target.
DIABETES :: Monograph
Breaking the Cycle: Using Incretin-Based Therapies to Overcome Clinical Inertia in Type 2 Diabetes
Incretin-based therapies, with their unique pathophysiology, have rapidly evolved into a therapeutic option that can fill this role. The symposium content, enhanced with an audience response system (ARS) and a case-based panel discussion, will concentrate on various critical aspects of successful type 2 diabetes disease management. Patient selection and strategies for advancement to incretin-based therapies are among the topics that will be discussed.
Incretin-based therapies, with their unique pathophysiology, have rapidly evolved into a therapeutic option that can fill this role. The symposium content, enhanced with an audience response system (ARS) and a case-based panel discussion, will concentrate on various critical aspects of successful type 2 diabetes disease management. Patient selection and strategies for advancement to incretin-based therapies are among the topics that will be discussed.
DIABETES :: Monograph
Peak Issues: Clinical Use Of Incretin-Based Therapies To Promote PPG Control In Type 2 Diabetes
This publication series will explore the science of PPG and its contribution to glycemic control, and highlight recent and emerging therapies that address this important target.
This publication series will explore the science of PPG and its contribution to glycemic control, and highlight recent and emerging therapies that address this important target.
DIABETES :: Monograph
Incretin Insider: incretin Mimetics 2008 in Review
A wealth of new data on incretin mimetics were released and published in 2008. This publication will summarize these key findings and offer insight into the clinical utility of incretin mimetics. This activity is intended for endocrinologists as well as other physicians and healthcare professionals treating patients with type 2 diabetes.
A wealth of new data on incretin mimetics were released and published in 2008. This publication will summarize these key findings and offer insight into the clinical utility of incretin mimetics. This activity is intended for endocrinologists as well as other physicians and healthcare professionals treating patients with type 2 diabetes.
INFLUENZA :: Teaching Kit
Antiviral Therapy for Influenza
Infectious disease specialists frequently act as consultants to primary care physicians and are therefore ideally qualified, by virtue of their training and function within the healthcare system, to educate their colleagues on this topic. This Teaching Kit provides several tools you can use to help other physicians address the multifaceted challenges of influenza management in view of recent guideline updates.
Infectious disease specialists frequently act as consultants to primary care physicians and are therefore ideally qualified, by virtue of their training and function within the healthcare system, to educate their colleagues on this topic. This Teaching Kit provides several tools you can use to help other physicians address the multifaceted challenges of influenza management in view of recent guideline updates.
DIABETES :: Webcast Series
Managing FPG and PPG With Incretin-Based Therapies: A Therapeutic Double Play
In the area of clinical management of diabetes, an urgent and ongoing need for appropriate treatment remains. In order to effectively manage this widespread disease, clinical professionals need to fully understand diabetes and its treatment options.
In the area of clinical management of diabetes, an urgent and ongoing need for appropriate treatment remains. In order to effectively manage this widespread disease, clinical professionals need to fully understand diabetes and its treatment options.
DIABETES :: Online Case Study
The Amazing Race to Tight Glycemic Control
Interactive Online CME Cases from IMP's ADA 2008 Symposium entitled 'THE AMAZING RACE to Tight Glycemic Control: Managing Complex Patients With Insulin Analogs'
Interactive Online CME Cases from IMP's ADA 2008 Symposium entitled 'THE AMAZING RACE to Tight Glycemic Control: Managing Complex Patients With Insulin Analogs'
DIABETES :: Webcast Series
ADA Summary Conference Report 2008
In Conjunction with the 2008 American Diabetes Association's 68th Annual Scientific Sessions this educational activity is designed to increase awareness and understanding of the role of incretin-based therapies in the treatment of patients with type 2 diabetes.
In Conjunction with the 2008 American Diabetes Association's 68th Annual Scientific Sessions this educational activity is designed to increase awareness and understanding of the role of incretin-based therapies in the treatment of patients with type 2 diabetes.
SEPSIS :: Applied Practical Learning
Early Identification and Treatment Protocols in Managing Severe Sepsis CD-ROM
This program will feature discussions by leading experts regarding severe sepsis recognition and management in adult patients. Participants will learn about current and emerging methods for early identification of severe sepsis, benefits of protocols for managing the condition, and resources for protocol development and implementation.
This program will feature discussions by leading experts regarding severe sepsis recognition and management in adult patients. Participants will learn about current and emerging methods for early identification of severe sepsis, benefits of protocols for managing the condition, and resources for protocol development and implementation.
INSOMNIA :: Webcast Series
Redefining Insomnia: State-of-the-Science in Insomnia Management
Incretin-based therapies not only offer the potential to address many of the pathophysiologic challenges of type 2 diabetes but also show great promise in addressing clinical challenges. This educational program will provide current information on pathophysiologic challenges in type 2 diabetes and potential solutions offered by incretin-based therapies.
Incretin-based therapies not only offer the potential to address many of the pathophysiologic challenges of type 2 diabetes but also show great promise in addressing clinical challenges. This educational program will provide current information on pathophysiologic challenges in type 2 diabetes and potential solutions offered by incretin-based therapies.
INSOMNIA :: Podcast Series
Redefining Insomnia: State-of-the-Science in Insomnia Management
This activity was developed for primary care physicians, psychiatrists, pharmacists, and other healthcare professionals involved in the
management of patients with chronic insomnia.
This activity was developed for primary care physicians, psychiatrists, pharmacists, and other healthcare professionals involved in the
management of patients with chronic insomnia.
INSOMNIA :: Applied Practical Learning
Redefining Insomnia: State-of-the-Science in Insomnia Management
This activity was developed for primary care physicians, psychiatrists, pharmacists, and other healthcare professionals involved in the
management of patients with chronic insomnia.
This activity was developed for primary care physicians, psychiatrists, pharmacists, and other healthcare professionals involved in the
management of patients with chronic insomnia.
INSOMNIA :: Monograph
Redefining Insomnia: State-of-the-Science in Insomnia Management
This activity was developed for primary care physicians, psychiatrists, pharmacists, and other healthcare professionals involved in the
management of patients with chronic insomnia.
This activity was developed for primary care physicians, psychiatrists, pharmacists, and other healthcare professionals involved in the
management of patients with chronic insomnia.
OBESITY :: Applied Practical Learning
Cardiometabolic Risk Reduction in the Metabolic Syndrome and Type 2 Diabetes
This activity was developed for physicians, nurses, and pharmacists involved in the management of patients with obesity and cardiometabolic risk factors.
This activity was developed for physicians, nurses, and pharmacists involved in the management of patients with obesity and cardiometabolic risk factors.
